AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1591977
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg) after morphine (16 mg/70 kg)
Trial: 10572333
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication (specific type not mentioned)
Trial: 31674641
Drug: High-Dose Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High-Dose Teriparatide (40-μg daily) + Denosumab (60 mg)
Trial: 31674641
Drug: Standard-Dose Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-Dose Teriparatide (20-μg daily) + Denosumab (60 mg)
Trial: 20858609
Drug: Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Therapy Alone
Trial: 16569929
Drug: NaHCO3 4.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 4.2% injected as a bolus (rapid infusion)
Trial: 16569929
Drug: NaHCO3 4.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 4.2% administered over a 30-min period (slow infusion)
Trial: 16569929
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (rapid and slow infusion)
Trial: 1450091
Drug: Nicorandil (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10-40 mg/day, b.i.d.)
Trial: 1450091
Drug: Diltiazem (60-240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60-240 mg/day, b.i.d.)
Trial: 1270971
Drug: Ethanol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (various doses)
Trial: 6420817
Drug: Ethanol (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (one dose level)
Trial: 23351590
Drug: Escitalopram (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (single dose)
Trial: 24892763
Drug: Control (hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (hepatitis vaccine)
Trial: 22846389
Drug: Self-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered cognitive behavior therapy (CBT)
Trial: 23759286
Drug: Standard cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive behavior therapy (CBT)
Trial: 15772927
Drug: Normal hemoglobin
RxNorm normalized name: Abnormal hemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal hemoglobin level (135-160 g/L) achieved with epoetin alfa (n=10)
Trial: 15772927
Drug: Subnormal hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subnormal hemoglobin level (90-120 g/L) (n=14)
Trial: 8775035
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine anaesthesia
Trial: 28934782
Drug: Full-dose ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose ketoprofen (0.5 mg/kg every 6 hours for 48 hours)
Trial: 28934782
Drug: Low-dose ketoprofen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketoprofen (half doses and quarter doses)
Trial: 26424510
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with a cast
Trial: 9863784
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg inhaled zanamivir, twice daily for 5 days
Trial: 9863784
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 5 days
Trial: 31444050
Drug: LH, sex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH, sex hormone‐binding globulin (SHBG), and anti‐Müllerian hormone (AMH)
Trial: 28713084
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy + Acupuncture + Vestibular rehabilitation
Trial: 28713084
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy + Acupuncture
Trial: 23604551
Drug: Oral strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral strategy with sitagliptin 100 mg/day
Trial: 23604551
Drug: Injectable strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable strategy with liraglutide starting at 0.6 mg/day, up-titrated to 1.2 mg/day after 1 week
Trial: 21767371
Drug: Heparin-bonded endoluminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded endoluminal bypass
Trial: 19836774
Drug: Denosumab 60
RxNorm normalized name: denosumab 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 60 mg subcutaneous every 6 months for 36 months
Trial: 17097943
Drug: Calcineurin inhibitors
RxNorm normalized name: Calcineurin inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitors (CNIs)
Trial: 15236812
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no disulfiram treatment)
Trial: 28129779
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (exercise, health education, socialization and group auditory rehabilitation (GAR)) attending YMCA twice a week for 10 weeks.
Trial: 23537458
Drug: liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.2 mg
Trial: 23537458
Drug: liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg
Trial: 25263744
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (Genotropin(®) 0.033 mg/kg/day) for 2 years
Trial: 25263744
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment in the first year, double dose in the second year)
Trial: 18540252
Drug: L-T4 therapy
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-T4 therapy with appropriate doses, improvement of clinical findings, normalization of serum total T4 levels, and persistently high TSH concentrations.
Trial: 18540252
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with adequate suppression of TSH (<6 mU/l) with therapy.
Trial: 9845400
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg octreotide acetate
Trial: 30318128
Drug: Wax bath
RxNorm normalized name: Candelilla Wax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wax bath treatment
Trial: 30318128
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with daily home exercises
Trial: 23149178
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg intravenous omeprazole
Trial: 23149178
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg intravenous omeprazole
Trial: 23149178
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of omeprazole
Trial: 21718094
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump therapy started at diagnosis
Trial: 21718094
Drug: Standard multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multiple daily insulin injections (MDIs)
Trial: 19786862
Drug: Morphine (10‐70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10‐70 microg x kg(‐1) x h(‐1))
Trial: 15818288
Drug: Gatifloxacin 10
RxNorm normalized name: GATIFLOXACIN 10MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 10 mg/kg once daily for 10 days
Trial: 15818288
Drug: Amoxicillin/clavulanate 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 90 mg/6.4 mg in 2 divided doses for 10 days
Trial: 12861138
Drug: 17beta-estradiol tablet
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol tablet placed in the inner one third of the vagina
Trial: 12861138
Drug: 17beta-estradiol tablet
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol tablet placed in the outer one third of the vagina
Trial: 9824602
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg twice daily for five days
Trial: 9824602
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily for five days
Trial: 159510
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period with no treatment
Trial: 2496740
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg recombinant tissue plasminogen activator (rt-PA) over five hours
Trial: 20362978
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy techniques adherence (cognitive methods and negotiating content/structuring sessions)
Trial: 12172954
Drug: Intra-articular high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular high molecular weight hyaluronan injection after arthrocentesis
Trial: 12172954
Drug: No arthrocentesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No arthrocentesis before hyaluronan injection
Trial: 7873109
Drug: Dance-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance-based exercise program (12 weeks, twice weekly)
Trial: 2240504
Drug: Prolonged infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged infusions of propofol
Trial: 359081
Drug: Mianserin 20
RxNorm normalized name: mianserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 20 mg three times daily plus placebo lithium tablets
Trial: 359081
Drug: Lithium tablets
DrugBank: Lithium succinate (DB14508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium tablets once daily plus placebo mianserin tablets
Trial: 359081
Drug: Mianserin 20
RxNorm normalized name: mianserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 20 mg three times daily (increased to 30 mg t.d.s. after one year)
Trial: 359081
Drug: Lithium tablets
DrugBank: Lithium succinate (DB14508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium tablets once daily
Trial: 21809362
Drug: BMS-790052 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-790052 (1, 10, 30, 60, and 100 mg, once-daily or 30 mg twice-daily)
Trial: 19734380
Drug: Acupuncture (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (8 weekly sessions using four bilateral acupuncture points)
Trial: 16455695
Drug: 20 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mug oral misoprostol solution at hourly intervals
Trial: 16455695
Drug: Vaginal dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal dinoprostone gel at six hourly intervals
Trial: 12677735
Drug: Intra-nasal mometasone
RxNorm normalized name: mometasone Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-nasal mometasone furoate (MF) 200 mg once daily
Trial: 31613942
Drug: Feather-edge preparation
RxNorm normalized name: Gallus gallus feather
DrugBank: Gallus gallus feather (DB10420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feather-edge preparation (Group 1)
Trial: 31613942
Drug: Chamfer preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamfer preparation (Group 2)
Trial: 25509262
Drug: Xuebijing Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing Injection (50 mL XI in 100 mL normal saline, injected twice daily for 3 days post-THA)
Trial: 25509262
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine perioperative therapies only)
Trial: 20333473
Drug: ECMO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECMO therapy
Trial: 17697016
Drug: protease inhibitor-based
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: protease inhibitor-based antiretroviral therapy
Trial: 16259547
Drug: Risperidone at
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone at flexible doses of 0.5 to 1.5 mg/day
Trial: 12080281
Drug: Pyridoxine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (100 mg)
Trial: 6365468
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fentiazac twice daily for 6 weeks
Trial: 6365468
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg indomethacin twice daily for 6 weeks
Trial: 6365468
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fentiazac twice daily for 2 weeks
Trial: 6365468
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg phenylbutazone twice daily for 2 weeks
Trial: 26717405
Drug: OraQuick Rapid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OraQuick Rapid HIV‐1/2 antibody test
Trial: 11986955
Drug: Cyclosporine (CsA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CsA) treatment
Trial: 18488812
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg delayed-released tablet (test formulation) without food
Trial: 18488812
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg delayed-released tablet (test formulation) with food
Trial: 18488812
Drug: Reference pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference pantoprazole 40 mg delayed-released tablet
Trial: 10699344
Drug: Biojector(R) jet-injection
RxNorm normalized name: Humulin R Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biojector(R) jet-injection system
Trial: 10699344
Drug: Needle injection
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle injection method
Trial: 8466095
Drug: Ventolin metered-dose
RxNorm normalized name: albuterol Metered Dose Inhaler [Ventolin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin metered-dose inhaler (VMDI)
Trial: 3780329
Drug: Alprazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.5 mg bid)
Trial: 3281449
Drug: Ferric polymaltose
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric polymaltose at a dose of 100 mg elemental iron twice daily for 56 days (group 1a)
Trial: 3281449
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered on the same schedule (group 1b)
Trial: 3281449
Drug: Ferric polymaltose
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric polymaltose at a dose of 100 mg elemental iron twice daily for 56 days (group 2a)
Trial: 3281449
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered on the same schedule (group 2b)
Trial: 21114777
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with 5‐fluorouracil/cisplatin (FP) (arm B)
Trial: 2886561
Drug: Diuretics alone
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics alone
Trial: 18208835
Drug: Diuretics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics plus irbesartan
Trial: 18208835
Drug: Diuretics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics plus ramipril
Trial: 17010798
Drug: Famotidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (20 to 40 mg)
Trial: 17010798
Drug: Famotidine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (30 mg/day for 6 months)
Trial: 11767419
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control (similar to the supplement in the pilot study)
Trial: 9043728
Drug: Sevoflurane 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane 1.0 to 1.5% (end-tidal) with nitrous oxide 66% in oxygen; anaesthesia induced with 5 mg.kg-1 thiopentone.
Trial: 8330464
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg alprazolam daily
Trial: 8330464
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg alprazolam daily
Trial: 3487646
Drug: D-penicillamine (DP)
DrugBank: Penicillamine (DB00859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-penicillamine (DP) 500 mg daily
Trial: 3487646
Drug: D-penicillamine (DP)
DrugBank: Penicillamine (DB00859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-penicillamine (DP) 125 mg daily
Trial: 15988076
Drug: Amoxicillin (40-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40-45 mg/kg/24 h) + Sinupret (mucoregulatory remedy)
Trial: 15988076
Drug: Amoxicillin (40-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (40-45 mg/kg/24 h)
Trial: 12848587
Drug: ALX 111
RxNorm normalized name: ALX-009
DrugBank: ALX-009 (DB17916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALX 111 (parathyroid hormone (1-84), rhPTH (1-84))
Trial: 8508724
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug counselling
Trial: 3518966
Drug: Norfloxacin (NOR)
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin (NOR) 400 mg bid for 7 days
Trial: 3518966
Drug: Pipemidic acid
RxNorm normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipemidic acid (PA) 400 mg bid for 7 days
Trial: 16135834
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg, single intravenous infusion)
Trial: 15264777
Drug: Oxiplex/SP Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiplex/SP Gel (1-3 ml) applied at the conclusion of surgery
Trial: 7586105
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg i.v.)
Trial: 7944469
Drug: Intraperitoneal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal treatment with MMC‐CH
Trial: 7944469
Drug: No anti‐cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti‐cancer drugs (Control)
Trial: 19905912
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg + Loratadine 10 mg
Trial: 19905912
Drug: Beclomethasone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone 200 mu g/twice daily
Trial: 7636321
Drug: Combined hyperthermia
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hyperthermia and radiotherapy (30.0 Gy in 2 weeks or 34.5 Gy in 3 weeks with heat treatments)
Trial: 7636321
Drug: Schedule A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A: 30.0 Gy with heat twice weekly (4 treatments)
Trial: 7636321
Drug: Schedule B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule B: 34.5 Gy with heat once weekly (3 treatments)
Trial: 7636321
Drug: Schedule C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule C: 34.5 Gy with heat twice weekly (6 treatments)
Trial: 18358541
Drug: Continuation-phase cognitive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation-phase cognitive therapy (C‐CT)
Trial: 26425812
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (6 mm)
Trial: 26425812
Drug: Long implants
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long implants (11-15 mm) with sinus grafting
Trial: 25476084
Drug: Traditional silica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional silica gel tube
Trial: 22113345
Drug: 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg aleglitazar
Trial: 22113345
Drug: 3000 μg
RxNorm normalized name: immunoglobulin G, human 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 μg aleglitazar
Trial: 17620371
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of imipenem-cilastatin (loading dose of 1 g/1 g, followed by 2 g/2 g per 24 h for 3 days)